These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 4590070)

  • 1. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

  • 2. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 5. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 7. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 8. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 10. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 11. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 12. Bensarazid with L-dopa in the treatment of parkinson's disease.
    Van Wieringen A
    S Afr Med J; 1974 Feb; 48(6):206-9. PubMed ID: 4814495
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 14. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R; Kvan L; Presthus J; Thoresen GB
    Acta Neurol Scand Suppl; 1972; 51():121-2. PubMed ID: 4514336
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
    Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 18. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 19. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.